Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Beta-carotene warning

This article was originally published in The Tan Sheet

Executive Summary

The Center for Science in the Public Interest is pushing FDA to require manufacturers of beta-carotene dietary supplements to warn smokers or people exposed to asbestos of an increased risk of lung cancer if they take supplements containing large doses of synthetic beta-carotene. CSPI says that supplements with more than 5,000 IU, or 3 mg, should bear warning notices and FDA should take action against companies that do not label accordingly. Companies including Nature Made and GNC market pills with 25,000 IU or 15 mg of beta-carotene, the center claims. The Food and Nutrition Board of the Institute of Medicine, a panel of the National Institutes of Health and others have separately determined that beta-carotene supplementation is risky for smokers and asbestos-exposed populations. A study published earlier this year in the Journal of the American Medical Association found beta carotene intake associated with a 7% increase in mortality rates among participants, though the study was challenged by trade groups (1"The Tan Sheet" March 5, 2007, p. 17)...

You may also be interested in...



Industry, Researchers Pan Study Showing Antioxidants May Up Mortality Risk

Trade groups and researchers say faulty methodology was used in a meta-analysis concluding that antioxidant supplements may increase mortality risk

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Partisan Politics Returns To US FDA Congressional Oversight

The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS101171

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel